Results 111 to 120 of about 1,140,406 (257)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Scalable treatment algorithm focused on hypertension management for the University of California. [PDF]

BMJ Open Qual
Kishore SP, Martin HE, Friedberg N, Narang P, Sak R, Skootsky SA, UC Way Hypertension Initiative Medication Use Collaborators.   +6 more
europepmc   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

A system-wide snapshot: A multi-campus survey of open source contributors at the University of California. [PDF]

PLoS One
Scarlett VT, Curty RG, Gomez J, Langdon L, Janée G, Budden AE.   +5 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Patient Perspectives and Concerns Regarding Cataract Surgery and Cataract Surgery Sedation: A Qualitative Study

Clinical Ophthalmology
Liam Molina,1 Nora Lyang,2 Rachel Schwartz,1,3 Neeti Parikh,1,4 Saras Ramanathan,1,4 Alison J Huang,1,5,6 Catherine L Chen1,3,7 1School of Medicine, University of California San Francisco, San Francisco, CA, USA; 2Western University of Health Sciences ...
Molina L, Lyang N, Schwartz R, Parikh N, Ramanathan S, Huang AJ, Chen CL   +6 more
doaj  

Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-World Study at the University of California. [PDF]

Cancers (Basel)
Jan T, Chen M, Chan FY, Kuderer N, Chan A.   +4 more
europepmc   +1 more source

COVID-19 outcomes in patients with cancer: Findings from the University of California health system database. [PDF]

Cancer Med, 2022
Kwon DH, Cadena J, Nguyen S, Chan KHR, Soper B, Gryshuk AL, Hong JC, Ray P, Huang FW.   +8 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Intraoperative functional brain mapping for glioma surgery: a comprehensive review of the University of California San Francisco mapping protocol. [PDF]

J Neurooncol
Chen JS, Bergsneider B, Haddad AF, Morshed RA, Hervey-Jumper SL, Young JS, Berger MS.   +6 more
europepmc   +1 more source